InnoCore Enters Exclusive License Agreement With Allergan
InnoCore Pharmaceuticals recently announced it has signed an exclusive license and collaboration agreement with Allergan, Inc. Under the agreement, the companies will expand their existing collaboration and jointly continue to develop long-acting ocular drug delivery products for the treatment of ophthalmic diseases.
Utilizing its patented SynBiosys polymeric drug delivery platform, InnoCore will formulate Allergan’s proprietary drugs into pharmaceutical products expected to be capable of sustained release for many months following a single ocular injection. The SynBiosys drug delivery platform is based on novel biodegradable multi-block co-polymers with unique molecular architectures that allow precise and site-specific delivery of drugs for predetermined periods of time, ranging from weeks to many months.
“We are very excited that we have expanded this important partnership with Allergan, a company that is widely recognized as a leading company in the development of controlled-release ophthalmology medicines,” said Jan Hendriks, Chief Executive Officer of InnoCore Pharmaceuticals. “Expanding our partnership with Allergan is a great opportunity for us to further grow InnoCore in line with our ambitions.”
InnoCore Pharmaceuticals is a specialty pharmaceutical company focused on the development and manufacturing of long-acting injectable drug delivery products for the treatment of chronic diseases. Utilizing its proprietary drug delivery technologies, such as its unique SynBiosys polymer platform, InnoCore develops biodegradable sustained-release depots for precisely controlled delivery of therapeutic compounds. Depot technologies include microspheres, solid implants, coatings, and gels. For more information, www.innocorepharma.com.
Allergan is a multi-specialty healthcare company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. For more information, visit www.allergan.com.
Total Page Views: 1163
